Jemperli fachinfo
WebAug 17, 2024 · JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced: endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen, or WebIntroducing JEMPERLI (dostarlimab), the first licensed monotherapy immunotherapy for recurrent/advanced dMMR/MSI-H endometrial cancer. 1. JEMPERLI is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer …
Jemperli fachinfo
Did you know?
WebJEMPERLI contains the active substance dostarlimab, which is a monoclonal antibody, a type of protein designed to recognise and attach to a specific target substance in the body. JEMPERLI works by helping your immune system fight your cancer. It is given when endometrial cancer (cancer of the lining of the womb) has spread, or cannot be taken WebJEMPERLI can cause immune-mediated hepatitis, which can be fatal. Grade 3 hepatitis occurred in 0.5% (3/605) of patients. Adrenal Insufficiency. Adrenal insufficiency occurred in 1.2% (7/605) of patients, including Grade 2 (0.5%) and Grade 3 (0.7%). For Grade 2 or higher adrenal insufficiency, initiate symptomatic treatment per institutional ...
WebFeb 26, 2024 · The full indication is: Jemperli is indicated as monotherapy for the treatment of adult patients with recurrent or advanced dMMR/MSI-H endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. Jemperli must be initiated and supervised by specialist physicians experienced in the treatment of … WebFeb 27, 2024 · Jemperli (dostarlimab-gxly) is a programmed death receptor-1 (PD-1)–blocking antibody used to treat adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
WebApr 22, 2024 · JEMPERLI was generated by AnaptysBio using its proprietary somatic hypermutation (SHM) antibody platform and subsequently developed by TESARO, Inc., now a part of GSK, under a collaboration agreement. WebJEMPERLI (dostarlimab for injection) January 31, 2024 6Page of 34 • Subsequent dosing beginning 3 weeks after Dose 4 (Dose 5 onwards): 1,000 mg every 6 weeks The dosage regimen is presented in Table 1. Table 1 Dosage regimen for patients treated with JEMPERLI Administer JEMPERLI as an intravenous infusion over 30 minutes.
WebÜber die Anwendung von JEMPERLI bei Patientinnen im Alter über 75 Jahren liegen nur begrenzte klinische Daten vor (siehe Abschnitt 5.1). Eingeschränkte Nierenfunktion . Bei Patientinnen mit leichter oder mittelschwerer Einschränkung der Nierenfunktion wird keine Dosierungsanpassung empfohlen.
WebJun 28, 2024 · Jemperli is a medicine that may treat certain cancers by working with your immune system. Jemperli can cause your immune system to attack normal organs and … red dawn cubanWebJun 2, 2024 · Jemperli is a prescription-only medicine supplied as a concentrate for solution for infusion that is injected into the veins. The recommended dosage is 500 mg … red dawn dailymotionWebJEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced : … red dawn cuevanaWebApr 29, 2024 · Listen to a soundcast of the April 22 & 23 2024 FDA approvals of Jemperli (dostarlimab-gxly) for patients with mismatch repair deficient recurrent or advanced endometrial cancer and Zynlonta ... knit lace curtain patternWebApr 22, 2024 · JEMPERLI is a programmed death receptor-1 (PD-1)-blocking antibody that binds to the PD-1 receptor and blocks its interaction with the PD-1 ligands PD-L1 and PD-L2. xiii In addition to GARNET, JEMPERLI is being investigated in other registrational enabling studies, as monotherapy and as part of combination regimens for women with recurrent … knit lacered dawn darylWebApr 12, 2024 · 今年2月，美国食品药品监督管理局（FDA）已常规批准Jemperli（dostarlimab，中文名：多塔利单抗）用于治疗复发或晚期子宫内膜癌的患 … knit lace borders free patterns